Onkológia 5/2024

Ocular graft-versus-host disease and its treatment options

Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative treatment option for a variety of hematologic malignancies and several nonmalignant hematologic diseases. Graft-versus-host disease (GvHD) is a multisystemic disease, which may affect several organs. It is initiated when alloreactive donor immune cells recognize immunologically disparate antigens in the host despite the use of standard immunosupressive prophylaxis. Acute and chronic GvHD| remain leading causes of morbidity and mortality after HSCT. Ocular GvHD remains a significant clinical complication after HSCT. Diagnosis and therapy of this complication involve multidisciplinary approach remain challenging for both hematologists and ophtalmologists. This review summarizes clinical characteristics and provide insights into the ocular GvHD treatments.

Keywords: ocular graft-versus-host disease, clinical symptoms, novel therapeutic modalities, tear biomarkers